{"schema_version":"secwatch.filing_event.v1","accession":"0001576280-24-000189","form_type":"8-K","ticker":"GH","cik":"0001576280","company_name":"Guardant Health, Inc.","filed_at":"2024-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.604122+00:00","generated_at":"2026-05-31T11:45:10.195964+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Guardant Health Q2 revenue up 29% to $177.2M, raises FY2024 guidance; FDA approves Shield CRC test","bullets":["Revenue $177.2M (+29% YoY); precision oncology revenue $166.5M (+33%).","GAAP net loss $102.6M ($0.84/share); non-GAAP net loss $58.5M ($0.48 loss).","FY2024 revenue guidance raised to $690-700M (prior $675-685M), growth 22-24%.","Shield blood test received FDA approval for first-line CRC screening; commercial launch; Medicare covers 45M beneficiaries.","Clinical tests 49,400 (+14%), biopharma tests 10,475 (+56%); cash $1.0B."],"urls":{"canonical":"https://secwatch.observer/filing/0001576280-24-000189","json":"https://secwatch.observer/filing/0001576280-24-000189.json","markdown":"https://secwatch.observer/filing/0001576280-24-000189.md","text":"https://secwatch.observer/filing/0001576280-24-000189.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1576280/000157628024000189/0001576280-24-000189-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1576280/000157628024000189/gh-20240807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:45:10.195964+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}